Search

Your search keyword '"Miyachi, Takafumi"' showing total 42 results
Start Over Author "Miyachi, Takafumi"
42 results on '"Miyachi, Takafumi"'

10. Deep vein thrombosis in patients with neuromuscular disease who undergo tracheotomy with positive pressure ventilation.

Author

Yamada, Hidetada, Nishikawa, Tomokazu, Yamasaki, Masami, Fukuba, Hiromasa, Ohmori, Hiromitsu, Nakamura, Mashio, and Miyachi, Takafumi

Subjects
POSITIVE pressure ventilation, VENOUS thrombosis, NEUROMUSCULAR diseases, TRACHEOTOMY, FEMORAL vein
Abstract

Background: Deep vein thrombosis and its progression to pulmonary thromboembolism is a major source of mortality in patients with neuromuscular disease. Furthermore, ventilator use poses a high risk of DVT to patients. Methods: Hospitalized patients with neuromuscular disease who underwent tracheotomy with positive pressure ventilation (TPPV) had DVT evaluated in the lower extremities by ongoing whole leg venous ultrasonography. Patients who were diagnosed with DVT underwent a second ultrasonography 1 month later. The attending physicians decided on therapeutic measures. All patients were followed during the study period. Results: Eight of 33 patients had DVT. The site of DVT formation was the iliac veins in three cases, femoral veins in two cases, and calf veins in three cases. All of the patients with DVT were asymptomatic. There was no difference in the clinical future between patients with DVT and those without DVT. Progression of DVT was not observed in the second ultrasonographic examination 1 month later. All patients with DVT had an excellent prognosis after a follow‐up period of 9 months. Conclusion: The prevalence of DVT in patients with neuromuscular disease who undergo TPPV might be high. Further large studies on this issue are required because the clinical significance of this DVT is uncertain. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. Relationship Between 3-O-methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson's Disease

Author

Ishihara, Aiko, Miyachi, Takafumi, Nakamura, Takeshi, Ohtsuki, Toshiho, Kimura, Yasuhiro, Kihira, Kenji, Yamawaki, Takemori, and Matsumoto, Masayasu

Subjects
3-OMD, Parkinson's disease, digestive, oral, and skin physiology, Levodopa AUC, Entacapone, nervous system diseases
Abstract

The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMTindex was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.

Published
2011

22. Incidence of Dementia, Alzheimer Disease, and Vascular Dementia in a Japanese Population: Radiation Effects Research Foundation Adult Health Study

Author

Yamada, Michiko, primary, Mimori, Yasuyo, additional, Kasagi, Fumiyoshi, additional, Miyachi, Takafumi, additional, Ohshita, Tomohiko, additional, Sudoh, Shinji, additional, Ikeda, Junko, additional, Matsui, Kazuko, additional, Nakamura, Shigenobu, additional, Matsumoto, Masayasu, additional, Fujiwara, Saeko, additional, and Sasaki, Hideo, additional

Published
2008
Full Text
View/download PDF

29. Ultrasonographic evaluation of bow hunter's syndrome.

Author

Nishitani, Michie, primary, Morino, Hiroyuki, additional, Matsuoka, Naoki, additional, Nomura, Eiichi, additional, Miyachi, Takafumi, additional, Maruyama, Hirofumi, additional, Kohriyama, Tatsuo, additional, Mimori, Yasuyo, additional, Matsumoto, Masayasu, additional, Naka, Hiromitsu, additional, and Kajikawa, Hiroshi, additional

Published
2004
Full Text
View/download PDF

38. Relationship Between 3-O-methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson's Disease

Author

Ishihara, Aiko, Miyachi, Takafumi, Nakamura, Takeshi, Ohtsuki, Toshiho, Kimura, Yasuhiro, Kihira, Kenji, Yamawaki, Takemori, Matsumoto, Masayasu, Ishihara, Aiko, Miyachi, Takafumi, Nakamura, Takeshi, Ohtsuki, Toshiho, Kimura, Yasuhiro, Kihira, Kenji, Yamawaki, Takemori, and Matsumoto, Masayasu

Abstract

The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMTindex was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.

39. [Burnout in Japanese neurologists: comparison of male and female physicians].

Author

Kubo M, Aiba I, Shimohata T, Hattori N, Yoshida K, Unno Y, Yokoyama K, Ogawa T, Kaseda Y, Koike R, Shimizu Y, Tsuboi Y, Doyu M, Misawa S, Miyachi T, Toda T, and Takeda A

Subjects
Adult, Asian People, Burnout, Professional epidemiology, Female, Humans, Internet, Japan epidemiology, Male, Middle Aged, Sex Factors, Surveys and Questionnaires, Burnout, Professional etiology, Neurologists psychology
Abstract

A questionnaire survey was conducted on 8,402 members of the Japanese Neurological Society to examine the current status and countermeasures for physician burnout, and 1,261 respondents (15.0%) responded. In this paper, we report the results of a comparison between male and female physicians. There was a significant difference in working and living conditions only for married people. It was confirmed that men work under stricter conditions in terms of working hours, and that the burden on women is heavier in the division of housework. Analysis using the Japanese Burnout Scale revealed no gender differences in overall scores, but as for factors related to burnout, in addition to factors common to both men and women, factors specific to men or women were clarified.

Published
2021
Full Text
View/download PDF

40. [Current and future strategies for burnout in Japanese neurologists].

Author

Shimohata T, Kubo M, Aiba I, Hattori N, Yoshida K, Unno Y, Yokoyama K, Ogawa T, Kaseda Y, Koike R, Shimizu Y, Tsuboi Y, Doyu M, Misawa S, Miyachi T, Toda T, and Takeda A

Subjects
Adult, Asian People, Burnout, Professional epidemiology, Depersonalization, Emotions, Female, Happiness, Humans, Japan epidemiology, Male, Middle Aged, Achievement, Burnout, Professional prevention & control, Burnout, Professional psychology, Job Satisfaction, Neurologists psychology, Surveys and Questionnaires
Abstract

To identify factors associated with burnout among Japanese physician and to use them in future measures, the Japanese Society of Neurology conducted a survey of neurologists on burnout using a web-based questionnaire in October 2019. A total of 1,261 respondents, 15.0% of the 8,402 members, responded to the survey. The mean of the subscales of the Japanese Burnout Scale was 2.86/5 points for emotional exhaustion, 2.21/5 points for depersonalization, and 3.17/5 points for lack of personal accomplishment. In addition, the burnout of our country's neurologists is not related to workloads such as working hours and the number of patients in charge, but also to a decreased meaningfulness and professional accomplishment. Therefore, it is necessary to take comprehensive measures to improve these issues at the individual, hospital, academic and national levels.

Published
2021
Full Text
View/download PDF

41. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.

Author

Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, and Matsumoto M

Subjects
Aged, Aged, 80 and over, Antiparkinson Agents pharmacokinetics, Aromatic Amino Acid Decarboxylase Inhibitors, Benserazide therapeutic use, Biomarkers blood, Carbidopa therapeutic use, Catechol O-Methyltransferase metabolism, Catechol O-Methyltransferase Inhibitors, Disease Progression, Dopa Decarboxylase metabolism, Drug Therapy, Combination, Female, Humans, Japan, Levodopa pharmacokinetics, Male, Middle Aged, Motor Activity drug effects, Parkinson Disease blood, Parkinson Disease diagnosis, Parkinson Disease psychology, Prospective Studies, Treatment Outcome, Tyrosine blood, Antiparkinson Agents therapeutic use, Catechols therapeutic use, Enzyme Inhibitors therapeutic use, Levodopa therapeutic use, Nitriles therapeutic use, Parkinson Disease drug therapy, Tyrosine analogs & derivatives
Abstract

The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.

Published
2011

42. [Folic acid deficiency].

Author

Miyachi T, Mimori Y, and Matsumoto M

Subjects
Dementia diagnosis, Dementia drug therapy, Diagnosis, Differential, Folic Acid administration & dosage, Humans, Hyperhomocysteinemia etiology, Injections, Intramuscular, Dementia etiology, Folic Acid Deficiency diagnosis, Folic Acid Deficiency drug therapy, Folic Acid Deficiency etiology, Folic Acid Deficiency physiopathology
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results